Add Yahoo as a preferred source to see more of our stories on Google. The FDA has approved a label change to Pfizer's contraceptive injection The US Food and Drug Administration (FDA) has approved a ...

Pfizer (NYSE:PFE) reported Phase 2b results for its GLP-1 anti-obesity candidate, PF-08653944, showing potential for a once ...

Pfizer hasn't yet tapped into the highly lucrative market of diabetes drugs that have been increasingly used for weight loss purposes. Searching for a weight-loss drug but don't like the idea of an ...

WASHINGTON -- The pharmaceutical giant Pfizer tightened its policies Friday regarding the use of drugs in lethal injections, a move experts said would make it harder for states to carry out executions ...

Eli Lilly’s Zepbound is still viewed as the leading weight-loss shot, according to a market analyst who compared the drug to a rival injection from Pfizer. The comment comes as drugmakers race to meet ...

Pfizer Inc. (NYSE: PFE) faces mounting legal challenges over claims that its contraceptive injection Depo-Provera (DMPA) is linked to brain tumors, with a key court hearing set for late September that ...

NVO and PFE clash as the obesity market heats up, with shifting strategies, pipeline bets and growth pressures reshaping ...

WASHINGTON (7News) — This week, the FDA approved a label change on Depo-Provera, requiring its maker, Pfizer, to warn women about links between use of the birth control injection and brain tumors ...

The company has not disclosed pricing or a launch timeline. The approval also comes as Novo Nordisk's Wegovy nears patent expiry later this month, potentially paving the way for lower-cost copycat ...

Thompsons Solicitors has confirmed it will help victims of Depo-Provera to seek legal damages after the Record highlighted the plights of multiple women left with life-altering injuries.